Kabeer Aziz - Sep 29, 2023 Form 4 Insider Report for AN2 Therapeutics, Inc. (ANTX)

Signature
/s/ Kabeer Aziz
Stock symbol
ANTX
Transactions as of
Sep 29, 2023
Transactions value $
-$1,704,513
Form type
4
Date filed
10/3/2023, 07:21 PM
Previous filing
Sep 29, 2023
Next filing
Nov 16, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ANTX Common Stock Sale -$1.36M -83.3K -3.84% $16.28 2.09M Sep 29, 2023 By Adjuvant Global Health Technology Fund, L.P. F1, F2, F3
transaction ANTX Common Stock Sale -$257K -15.8K -3.84% $16.28 395K Sep 29, 2023 By Adjuvant Global Health Technology Fund DE, L.P. F1, F2, F4
transaction ANTX Common Stock Sale -$76.7K -4.77K -0.23% $16.07 2.08M Oct 2, 2023 By Adjuvant Global Health Technology Fund, L.P. F1, F3, F5
transaction ANTX Common Stock Sale -$14.5K -902 -0.23% $16.07 394K Oct 2, 2023 By Adjuvant Global Health Technology Fund DE, L.P. F1, F4, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on December 8, 2022.
F2 The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $16.00 to $16.95, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F3 Shares held directly by Adjuvant Global Health Technology Fund, L.P. ("AGHT Fund"). The sole general partner of AGHT Fund is Adjuvant Capital GP, L.P. ("AC GP") and the sole general partner of AC GP is Adjuvant Capital Management, L.L.C. ("AC MGMT"). The Reporting Person is a member of the Issuer's board of directors and is Secretary of AC MGMT, and may be deemed to share voting and dispositive power over the securities held by such entities. Each such person and entity disclaims beneficial ownership of the securities, except to the extent of such person's or entity's pecuniary interest in such securities.
F4 Shares held directly by Adjuvant Global Health Technology Fund DE, L.P. ("AGHT Fund DE"). The sole general partner of AGHT Fund DE is AC GP and the sole general partner of AC GP is AC MGMT. The Reporting Person is a member of the Issuer's board of directors and is Secretary of AC MGMT, and may be deemed to share voting and dispositive power over the securities held by such entities. Each such person and entity disclaims beneficial ownership of the securities, except to the extent of such person's or entity's pecuniary interest in such securities.
F5 The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $16.00 to $16.10, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.